Q1 2027 Inventurus Knowledge Solutions Ltd Earnings Call Transcript
Key Points
- Inventurus Knowledge Solutions Ltd (NSE:IKS) delivered strong Q1 FY27 results with 21% year-on-year revenue growth (12% in constant currency) and 33% reported EBITDA, which rises to 35% after adjusting for one-time TruBridge acquisition costs.
- The company secured significant client wins, including a large California health system and Advocate Health, demonstrating the success of its land-and-expand strategy in the health system market.
- The TruBridge acquisition is expected to be EPS accretive, with the company confirming it inherited $68 million in annualized EBITDA and plans to drive synergies through technology and offshore leverage.
- Inventurus Knowledge Solutions Ltd (NSE:IKS) is building proprietary small language models (SLMs) and explainable AI using TruBridge's 5 million+ patient dataset, which is expected to reduce dependence on expensive commercial LLMs and create a long-term competitive moat.
- The company maintains a strong balance sheet and cash flow generation, with a True North goal of achieving INR3,000 crores in EBITDA by FY30 without significant dilution or additional debt.
- TruBridge's revenue base was reset lower by approximately $40 million annually due to conservative revenue recognition, unprofitable service lines, and anticipated customer discounts, which was not fully foreseen pre-close.
- The company's reported EBITDA margin of 33% was impacted by INR20 crores in one-time acquisition costs, and integration expenses are expected to continue in the near term.
- Inventurus Knowledge Solutions Ltd (NSE:IKS) faces increasing competitive intensity from point solutions like Abridge that are attempting to expand into broader platforms, which could pressure pricing.
- The company has not yet provided a clear revenue growth outlook for the TruBridge business, citing the need for 2-3 quarters to understand its growth potential, creating uncertainty for investors.
- The tax rate increased to 22.4% in Q1, and the company expects it to remain in the 22-23% range for the legacy IKS business, which could impact net profit growth.
Once again, ladies and gentlemen, good day and welcome to IKS Health. Q1 FY27 earnings conference call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Seema Nayak for ICICI Securities. Thank you and over to you, Ms. Seema Nayak.
Good morning, ladies and gentlemen. Thank you for joining us today on the Q1 FY27 call of IKS. On behalf of ICICI Securities, I would like to thank the management of IKSL for giving us the opportunity to host this call. Today we have with us Mr. Sachin Gpta, founder and CEO; Ms. Nitya Balasubramanian, CFO; and Mr. Saransh Mundra, Head of Investor Revisions. I turn it over to Mr. Saransh for his brief statement and to take the preceding call.
Thank you. Over to you, Saransh.
Thank you, Seema. Good morning to everyone. Thank you for attending our earnings call. We hope you had the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
